How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
obesity, lifting the fortunes and expectations for market leaders Novo Nordisk ( NVO ) and Eli Lilly ( LLY Both companies will report first quarter earnings this week — Lilly on April 30 and Novo on May 2 — and all eyes will be on their GLP-1 portfolios. Wall Street estimates Eli Lilly will bring in revenue of $8.9 billion, up from nearly $7 billion in the first quarter of 2023; Novo Nordisk, meanwhile, is expected to report at least $9 billion, compared to $7.2 billion last year, according to Bloomberg. Analysts expect Ozempic and Wegovy combined to bring in sales of $26 billion for Novo for the full year 2024, and Mounjaro and Zepbound could net Lilly about $13.5 billion, according to Bloomberg. Novo's blockbuster drugs — Ozempic to treat diabetes and Wegovy, for weight loss — are also known by their formula name, semaglutide. Lilly's key drugs — Mounjaro for diabetes and Zepbound, for weight loss — are known by their formula name, tirzepatide. The diabetes drugs have been
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Ozempic maker Novo Nordisk says it will study drug's effects on alcohol consumption but isn't focused on addiction [Yahoo! Finance]Yahoo! Finance
- Ozempic maker Novo Nordisk says it will study drug's effects on alcohol consumption but isn't focused on addiction [CNN]CNN
- Wegovy users may keep the weight off for 4 years, drug's maker says [CBS News]CBS News
- Ozempic maker Novo Nordisk says it will study drug's effects on alcohol consumption but isn't focused on addiction [CNN]CNN
- UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/15/24 - Form 6-K
- 5/13/24 - Form 6-K
- 5/13/24 - Form 6-K
- NVO's page on the SEC website